170 related articles for article (PubMed ID: 37317505)
1. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
DeKoven S; Naccarato M; Brumme CJ; Tan DHS
HIV Med; 2023 Nov; 24(11):1137-1143. PubMed ID: 37317505
[TBL] [Abstract][Full Text] [Related]
2. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
[TBL] [Abstract][Full Text] [Related]
3. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
4. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
5. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
Buzon-Martin L; Navarro-San Francisco C; Fernandez-Regueras M; Sanchez-Gomez L
J Antimicrob Chemother; 2024 May; 79(5):1153-1156. PubMed ID: 38558010
[TBL] [Abstract][Full Text] [Related]
6. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
[TBL] [Abstract][Full Text] [Related]
7. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
Stellbrink HJ; Lazzarin A; Woolley I; Llibre JM
HIV Med; 2020 Mar; 21 Suppl 1():3-16. PubMed ID: 32017355
[TBL] [Abstract][Full Text] [Related]
8. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.
Tsai MS; Sun HY; Chen CP; Lee CH; Lee CY; Liu CE; Tang HJ; Hung TC; Li CW; Lee YT; Liou BH; Yang CJ; Hung CC;
Int J Infect Dis; 2023 Jan; 126():39-47. PubMed ID: 36384186
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Florence E; Yombi JC; Henrard S; Darcis G; Van Praet J; Vandekerckhove L; Allard SD; Demeester R; Messiaen P; Ausselet N; Delforge M; De Wit S;
HIV Med; 2023 Aug; 24(8):914-924. PubMed ID: 37038245
[TBL] [Abstract][Full Text] [Related]
10. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Hidalgo-Tenorio C; Sequera S; Vivancos MJ; Vinuesa D; Collado A; Santos IL; Sorni P; Cabello-Clotet N; Montero M; Font CR; Terron A; Galindo MJ; Martinez O; Ryan P; Omar-Mohamed M; Albendín-Iglesias H; Javier R; Ruz MÁL; Romero A; Garcia-Vallecillos C
Int J Antimicrob Agents; 2024 Jun; 63(6):107164. PubMed ID: 38574873
[TBL] [Abstract][Full Text] [Related]
11. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
[TBL] [Abstract][Full Text] [Related]
12. Biktarvy for the treatment of HIV infection: Progress and prospects.
De Clercq E; Zhang Z; Huang J; Zhang M; Li G
Biochem Pharmacol; 2023 Nov; 217():115862. PubMed ID: 37858869
[TBL] [Abstract][Full Text] [Related]
13. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.
Torralba M; Rodríguez G; González Gasca FJ; Cuadra F; Barberá J; Geijo P; Silva A; García MI; Ostaiza MA; García Pérez AM; Arroyo E; Larrubia JR; Gutiérrez A; Porras ML; Calvo Sánchez H; Peña-Asensio J; Arias JG; Mendoza I
Ann Pharmacother; 2024 Feb; 58(2):140-147. PubMed ID: 37131300
[TBL] [Abstract][Full Text] [Related]
14. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A; Tavelli A; Di Biagio A; Sarmati L; Marchetti GC; Bai F; Cingolani A; Quiros Roldan E; Mussini C; Lichtner M; Vergori A; Piconi S; Orofino G; Fusco FM; Bandera A; Nozza S; Castagna A; Antinori A;
J Antimicrob Chemother; 2024 Jun; 79(6):1279-1288. PubMed ID: 38581349
[TBL] [Abstract][Full Text] [Related]
16. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Grau S; Miró JM; Olalla J; Alcalá JC; Castro A; Rubio-Rodríguez D; Rubio-Terrés C
Expert Rev Anti Infect Ther; 2023 Jan; 21(1):65-76. PubMed ID: 36399521
[TBL] [Abstract][Full Text] [Related]
18. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
[TBL] [Abstract][Full Text] [Related]
19. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
20. Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis.
Sidman EF; Ondrush NM
Am J Health Syst Pharm; 2023 Apr; 80(9):e92-e97. PubMed ID: 36373751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]